Drug
Azercabtagene Zapreleucel
Azercabtagene Zapreleucel: highest development phase Phase 1, developed by TG Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- TG Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Azercabtagene zapreleucel (azer-cel) NCT06680037 | Phase 1 | B-cell Mediated Autoimmune Disorders |
Latest
No recent events.
Follow Azercabtagene Zapreleucel on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.